Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641135 | 1.00 | OPRK1 (0.48) | OPRK1KCNH2OPRM1PKMNPSR1 | |
| SCHEMBL29641090 | 1.00 | OPRK1 (0.48) | OPRK1KCNH2OPRM1PKMNPSR1 | |
| SCHEMBL29638013 | 1.00 | OPRK1 (0.48) | OPRK1KCNH2OPRM1PKMNPSR1 | |
| SCHEMBL15934617 | 1.00 | OPRK1 (0.48) | OPRK1KCNH2OPRM1PKMNPSR1 | |
| SCHEMBL6121340 | 0.87 | SLC6A4 (0.54) | OPRK1KCNH2ALDH1A1SLC6A4 | |
| SCHEMBL15405283 | 0.87 | SLC6A4 (0.54) | OPRK1KCNH2ALDH1A1SLC6A4 | |
| SCHEMBL29641206 | 0.87 | SLC6A4 (0.54) | OPRK1KCNH2ALDH1A1SLC6A4 | |
| SCHEMBL16765154 | 0.87 | SLC6A4 (0.54) | OPRK1KCNH2ALDH1A1SLC6A4 | |
| SCHEMBL4031829 | 0.87 | CYP3A4 (0.53) | ALDH1A1 | |
| SCHEMBL7744542 | 0.83 | ALDH1A1 (0.53) | OPRK1KCNH2OPRM1PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | OPRK1 3296/4885KCNH2 1822/4885OPRM1 2697/4885 |
| US-20190211033-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | OPRK1 3296/4885KCNH2 1822/4885OPRM1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.